Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor

The Journal of Urology
Ricardo LeãoRobert J Hamilton

Abstract

Retroperitoneal lymph node dissection is recommended for residual masses greater than 1 cm after chemotherapy of nonseminomatous germ cell tumors. Currently there is no reliable predictor of post-chemotherapy retroperitoneal lymph node dissection histology. Up to 50% of patients harbor necrosis/fibrosis only so that a potentially morbid surgery has limited therapeutic value. In this study we evaluated the ability of defined serum miRNAs to predict residual viable nonseminomatous germ cell tumors after chemotherapy. Levels of serum miRNA, including miR-371a-3p, miR-373-3p and miR-367-3p, were measured using the ampTSmiR (amplification targeted serum miRNA) test in 82 patients, including 39 in cohort 1 and 43 in cohort 2, who were treated with orchiectomy, chemotherapy and post-chemotherapy retroperitoneal lymph node dissection. miRNA levels were compared to clinical characteristics and serum tumor markers, and correlated with the presence of viable germ cell tumor vs fibrosis/necrosis and teratoma. ROC analysis was done to determine miRNA discriminative capacity. miRNA levels were significantly associated with disease extent at chemotherapy and they decreased significantly after chemotherapy. Conventional serum tumor marker leve...Continue Reading

References

May 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E W SteyerbergJ P Donohue
Jul 13, 2005·Cell·Carlo M Croce, George A Calin
Nov 23, 2006·Seminars in Cancer Biology·Konrad HuppiNatasha J Caplen
Sep 26, 2007·The Journal of Pathology·A J M GillisL H J Looijenga
Nov 14, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brett S CarverJoel Sheinfeld
Nov 12, 2010·Nature Reviews. Urology·LaMont J BarlowJames M McKiernan
Dec 22, 2010·American Journal of Clinical Pathology·Matthew J MurrayNicholas Coleman
Feb 8, 2011·European Urology·James W F CattoTapio Visakorpi
Dec 23, 2011·Actas urologicas españolas·P AlbersUNKNOWN European Association of Urology
Sep 4, 2012·European Urology·Siamak DaneshmandLori Wood
Nov 28, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P RaviC J Sweeney
Aug 9, 2016·European Urology·Klaus-Peter DieckmannGazanfer Belge
Jun 15, 2017·Cellular Oncology (Dordrecht)·Ton van AgthovenLeendert H J Looijenga
Jul 27, 2016·Oncotarget·Ton van Agthoven, Leendert H J Looijenga

❮ Previous
Next ❯

Citations

Mar 16, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Klaus-Peter DieckmannGazanfer Belge
Mar 7, 2018·Nature Reviews. Urology·Annette Fenner
Jan 24, 2020·Current Opinion in Urology·Lucia NappiCraig Nichols
Jan 7, 2020·Current Opinion in Urology·Dafina IlijaziIris E Ertl
Oct 28, 2019·Expert Review of Molecular Diagnostics·Michal ChovanecLiang Cheng
Feb 19, 2019·Oncotarget·Christina GuoMark Shackleton
Aug 18, 2020·Abdominal Radiology·Matthew A MorganDavid J Vaughn
Sep 26, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lucia NappiChristian Kollmannsberger
Oct 7, 2018·Nature Reviews. Disease Primers·Liang ChengLeendert H J Looijenga
Oct 17, 2018·International Journal of Molecular Sciences·Angelika TerbuchMartin Pichler
Sep 10, 2019·Expert Review of Molecular Diagnostics·Philip ZeuschnerKerstin Junker
Dec 12, 2018·Journal of Cellular and Molecular Medicine·Michal MegoLeendert H J Looijenga
Oct 30, 2019·International Journal of Molecular Sciences·Leendert H J LooijengaMuhammad T Idrees
Jan 13, 2019·International Journal of Molecular Sciences·João LoboLeendert H J Looijenga
Mar 12, 2020·Nature Reviews. Urology·Kristian AlmstrupKlaus-Peter Dieckmann
Jan 26, 2021·Critical Reviews in Oncology/hematology·Paolo PedrazzoliSimona Secondino
Feb 13, 2021·International Journal of Molecular Sciences·Marco De MartinoFrancesco Esposito
Apr 4, 2021·International Journal of Molecular Sciences·João LoboRui Henrique
Apr 25, 2021·Molecular Diagnosis & Therapy·John T LafinAditya Bagrodia
May 13, 2021·Journal of Pediatric Surgery·Jennifer H AldrinkPeter F Ehrlich
Jun 5, 2021·International Journal of Urology : Official Journal of the Japanese Urological Association·Satoshi NittaHiroyuki Nishiyama
Jul 16, 2021·Therapeutic Advances in Medical Oncology·Ciara Conduit, Ben Tran

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.